Honest Criticisms and Limitations of the REWIND Trial
A critical analysis of the REWIND cardiovascular outcomes trial for dulaglutide, covering enrollment biases, generalizability gaps, statistical nuances, and post-publication commentary.
Trials Rewind
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
8articles
3topic areas covered
May 25, 2026latest review
Trials Rewind library
Showing 8 of 8 clinical reviews.
Inside the REWIND Methodology: What Most Summaries Skip
A detailed breakdown of the REWIND trial's design, randomization, blinding, inclusion criteria, statistical framework, and how each methodological choice shapes the interpretation of dulaglutide's 12% MACE reduction.
REWIND Cost, Cost-Effectiveness, and Health-Economic Implications
How much does dulaglutide's 12% MACE reduction actually cost per QALY? A deep dive into the health-economic analyses built on REWIND, payer-coverage realities, and the value calculation for patients with type 2 diabetes.
REWIND Extension Data and What Happened After the Trial Ended
Deep dive into the REWIND trial's post-trial follow-up, durability of dulaglutide's cardiovascular benefit, long-term safety signals, and what extended observation revealed beyond the original 5.4-year median.
REWIND Results in Detail: Numbers, Subgroups, and Time Course
A deep dive into the REWIND trial's primary and secondary endpoint results for dulaglutide 1.5 mg in type 2 diabetes, including MACE effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of cardiovascular benefit.
REWIND Subgroup Analyses: Who Responded Most and Least to Dulaglutide
A deep dive into the pre-specified and post-hoc subgroup analyses from the REWIND cardiovascular outcomes trial of dulaglutide 1.5 mg in type 2 diabetes, covering age, sex, BMI, prior CVD status, race/ethnicity, and baseline biomarkers.
REWIND Trial: A Plain-English Overview of What It Established
A plain-English deep dive into the REWIND cardiovascular outcomes trial for dulaglutide (Trulicity) in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
What REWIND Actually Changes in Clinical Practice
A deep dive into the REWIND trial's 12% MACE reduction with dulaglutide and what it means for real-world prescribing in type 2 diabetes, including guideline updates, patient selection, and primary prevention implications.